BICD1

Across TCGA pan-cancer cohorts, BICD1 Mutation is linked to patient survival in 10 of 34 cancer types, making it a survival-associated BICD1 data layer compared with 23 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher BICD1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated BICD1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

ACC, UCEC, and COAD are the cancer types where BICD1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.010	0.667	<.001	45	view →
UCEC	DFS	Median	All	0.965	0.625	.014	16	view →
COAD	OS	Median	III,IV	0.140	0.792	<.001	15	view →
PCPG	OS	Median	All	0.009	0.946	<.001	12	view →
LUSC	OS	Median	III,IV	0.001	0.665	<.001	12	view →
LIHC	DFS	Median	II,III,IV	0.077	0.463	.002	9	view →
CESC	OS	Median	All	0.287	0.798	.017	6	view →
GBM	DFS	Median	All	0.043	0.243	.003	6	view →
ESCA	OS	Median	II,III,IV	0.216	0.702	.014	6	view →
SKCM	OS	Median	III,IV	0.305	0.704	.011	2	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

BICD1–ACC (DFS)

Open the ACC breakdown →